Evidence map›Paper›PMID 37246725›Full record

ArticleJournal of veterinary internal medicine

Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats.

Maxime Kurtz, Virginie Fabrès, Renaud Dumont, Valérie Chetboul, Sabine Chahory, Vittorio Saponaro, Emilie Trehiou, Camille Poissonnier, Peggy Passavin, Coline Jondeau and 3 more

Abstract read
In one paragraph

Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. SomaticHypertension (Dallas, Tex. : 1979) · 2024
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maxime KurtzEcole Nationale Vétérinaire d'Alfort - CHUVA, Service de Médecine Interne, Maisons-Alfort, France.ORCID https://orcid.org/0000-0003-4494-2975
Virginie FabrèsEcole Nationale Vétérinaire d'Alfort - CHUVA, Service de Médecine Interne, Maisons-Alfort, France.
Renaud DumontCentre Hospitalier Veterinaire Fregis, Arcueil, France.ORCID https://orcid.org/0000-0001-6743-7387
Valérie ChetboulÉcole Nationale Vétérinaire d'Alfort - CHUVA, Unité de Cardiologie d'Alfort, Maisons-Alfort, France.ORCID https://orcid.org/0000-0001-7891-1814
Sabine ChahoryEcole Nationale Vétérinaire d'Alfort - CHUVA, Unité d'Ophtalmologie, Maisons-Alfort, France.
Vittorio SaponaroÉcole Nationale Vétérinaire d'Alfort - CHUVA, Unité de Cardiologie d'Alfort, Maisons-Alfort, France.
Emilie TrehiouÉcole Nationale Vétérinaire d'Alfort - CHUVA, Unité de Cardiologie d'Alfort, Maisons-Alfort, France.
Camille PoissonnierÉcole Nationale Vétérinaire d'Alfort - CHUVA, Unité de Cardiologie d'Alfort, Maisons-Alfort, France.
Peggy PassavinÉcole Nationale Vétérinaire d'Alfort - CHUVA, Unité de Cardiologie d'Alfort, Maisons-Alfort, France.
Coline JondeauEcole Nationale Vétérinaire d'Alfort - CHUVA, Unité d'Ophtalmologie, Maisons-Alfort, France.
Matthieu BottEcole Nationale Vétérinaire d'Alfort - CHUVA, Unité d'Ophtalmologie, Maisons-Alfort, France.
Thierry BuronfosseVetAgro Sup - Service De Biologie Clinique, Marcy-l'Etoile, France.
Ghita BenchekrounEcole Nationale Vétérinaire d'Alfort - CHUVA, Service de Médecine Interne, Maisons-Alfort, France.ORCID https://orcid.org/0000-0003-3947-5655

Funding

ECVIM-CA Clinical Studies Fund
6 · The paper itself

Abstract

backgroundIn a previous study, telmisartan suppressed aldosterone secretion in healthy cats but not in cats with primary hyperaldosteronism (PHA). HYPOTHESES: Telmisartan suppresses aldosterone secretion in middle-aged healthy cat and cats with diseases that may result in secondary hyperaldosteronism, but not in those with PHA. ANIMALS: Thirty-eight cats: 5 with PHA; 16 with chronic kidney disease (CKD), subclassified as hypertensive (CKD-H) or non-hypertensive (CKD-NH); 9 with hyperthyroidism (HTH); 2 with idiopathic systemic arterial hypertension (ISH); and 6 healthy middle-aged cats.

methodsProspective, cross-sectional study. Serum aldosterone concentration, potassium concentration, and systolic blood pressure were measured before and 1 and 1.5 hours after PO administration of 2 mg/kg of telmisartan. The aldosterone variation rate (AVR) was calculated for each cat.

resultsNo significant difference in the minimum AVR was observed among groups (median [quartile 1 (Q1); quartile 3 (Q3)]: 25 [0; 30]; 5 [-27; -75]; 10 [-6; -95]; 53 [19; 86]; 29 [5; 78]) for PHA, CKD, HTH, ISH, and healthy cats, respectively (P = .05). Basal serum aldosterone concentration (pmol/L) was significantly higher in PHA cats (median [Q1; Q3]: 2914 [2789; 4600]) than in CKD-H cats (median [Q1; Q3]: 239 [189; 577], corrected P value = .003) and CKD-NH cats (median [Q1; Q3]: 353 [136; 1371], corrected P value = .004). CONCLUSIONS AND CLINICAL IMPORTANCE: The oral telmisartan suppression test using a single dose of 2 mg/kg telmisartan did not discriminate cats with PHA from healthy middle-aged cats or cats with diseases that may result in secondary hyperaldosteronism.

Indexed as

Cat DiseasesHyperaldosteronismHypertensionRenal Insufficiency, ChronicAldosteroneAnimalsCatsCross-Sectional StudiesHypertension, RenalNephritisTelmisartanAldosteroneTelmisartanadrenaladrenal glandaldosteronecardiologycardiovascularendocrinologyhemodynamicshypertensionhypertrophic cardiomyopathyhypokalemiaretinopathy

Identifiers

PMID37246725
PMCPMC10365049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.